Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Other Non-Current Assets (2022 - 2025)

Historic Other Non-Current Assets for Zentalis Pharmaceuticals (ZNTL) over the last 4 years, with Q3 2025 value amounting to $3.2 million.

  • Zentalis Pharmaceuticals' Other Non-Current Assets rose 2204.04% to $3.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.2 million, marking a year-over-year increase of 2204.04%. This contributed to the annual value of $4.4 million for FY2024, which is 3521.56% down from last year.
  • According to the latest figures from Q3 2025, Zentalis Pharmaceuticals' Other Non-Current Assets is $3.2 million, which was up 2204.04% from $3.2 million recorded in Q2 2025.
  • Zentalis Pharmaceuticals' 5-year Other Non-Current Assets high stood at $6.8 million for Q4 2023, and its period low was $2.6 million during Q2 2022.
  • Moreover, its 4-year median value for Other Non-Current Assets was $2.7 million (2024), whereas its average is $3.2 million.
  • In the last 5 years, Zentalis Pharmaceuticals' Other Non-Current Assets skyrocketed by 15953.56% in 2023 and then plummeted by 3521.56% in 2024.
  • Zentalis Pharmaceuticals' Other Non-Current Assets (Quarter) stood at $2.6 million in 2022, then skyrocketed by 159.54% to $6.8 million in 2023, then tumbled by 35.22% to $4.4 million in 2024, then fell by 27.42% to $3.2 million in 2025.
  • Its Other Non-Current Assets stands at $3.2 million for Q3 2025, versus $3.2 million for Q2 2025 and $3.3 million for Q1 2025.